In this case report, we discuss the case of a patient with a <i>EWSR1-NFATC2</i> fusion positive bone sarcoma who had exceptional tumor control through using pazopanib and surgery for an overall duration exceeding 5 years. This evidence concerns the gene NFATC2 and bone sarcoma.